September 15, 2025

NRG Oncology Broadcast archives are accessible from our website at any time. Please bookmark this link for your convenience.

Annual Call for Committee Membership Applications

Are you interested in serving on an NRG Oncology committee? NRG Oncology depends on its members to advance its mission. Our members help drive our research, develop protocols, contribute to our science, and so much more. If you are interested in serving on an NRG Oncology research committee, or if you are a member who had previously served on a committee and would like to re-engage please consider applying by following the instructions in the 2025 NRG ONCOLOGY GENERAL AND CORE COMMITTEES APPLICATION FORM and submitting a complete application. 

OTHER PROTOCOL NOTICES

1. ALL DISEASE SITES

NRG-GY022: Reminder: Actively Recruiting MALE Patients only Read More

2. BIOSPECIMEN BANKS

Kit Shipments to Sites in Canada

Important information re: shipments of kits from BB Columbus to Sites in Canada. Please see the memorandum, dated August 18, 2025, posted on CTSU.

Printing Biospecimen Transmittal PDFs from Rave

Please note an effort is underway to clarify how to obtain a Biospecimen Transmittal PDF for submission to the NRG Oncology Biospecimen Bank. Read More

3. BRAIN

NRG-BN011: Beginning, September 12, 2025, please use the updated NRG-BN011 Gleostine® (lomustine) Clinical Trial Order form (posted on CTSU). An updated memo is also posted on CTSU.

4. BREAST

NRG-BR009/OFSET: Site-Directed Video Tools

5. CANCER PREVENTION & CONTROL

NRG-CC005/FORTE: Clinical research professionals can sign up for NRG Oncology Weekly Broadcasts to receive monthly FORTE Fridays updates directly to your inbox (click here).

NRG-CC014: A study overview video for participants and script have been approved by the CIRB. The materials are posted on CTSU.

The French and Spanish-translated EQ-5D-5L and Brief Pain Inventory (Short Form), along with CIRB’s approval of the questionnaires are available on CTSU.

6. GENITOURINARY

NRG-GU010: Veracyte Shipping update for sites in Canada – Due to an increase of shipments into the US being inspected, a more detailed commercial invoice should be included with each shipment to Veracyte. A memo with further details and template invoice is posted on CTSU.

NRG-GU015: Training Slides posted on CTSU.

7. GYNECOLOGIC

NRG-GY025: Now accruing to the Phase II portion. The Phase II ICD should be used for patients entered from this point forward. Documents are posted on CTSU.

NRG-GY026: To improve study statistical analysis and reporting processes, the Rave ‘Non-Protocol Therapy Reporting’ form for NRG-GY026 was updated September 3, 2025. The new form name is ‘Non-Protocol Therapy/Subsequent therapy’. See memo dated August 28, 2025, posted on CTSU.

Accruing patients of all stages and all histologic subtypes of endometrial cancer.

NRG-GY031: Please note there is an error in the section 4.2 table and the Biospecimen Collection and Submission Manual. The Part I PK collection is to be done on Cycle 1, Day 1, and Cycle 1, Day 8. This will be updated with the next amendment.

8. HEAD & NECK

NRG-HN008 - Reminder: Please update treatment and AE data weekly. This is a Phase I trial and timely data submission is very important. 

RTOG 1216: Attn sites in Canada! An IB signature page is posted on CTSU for version 22 of the Atezolizumab IB. Please submit via the form via the CTSU regulatory submission portal.

9. LUNG

NRG LU007: Attn sites in Canada! An IB signature page is posted on CTSU for version 22 of the Atezolizumab IB. Please submit via the form via the CTSU regulatory submission portal.

10. VTOC TRAINING

The VTOC Webinar Training Series schedule and registration is available for NRG Oncology Research Associates working on NRG-BN014, NRG-BR009, NRG-CC005, NRG-CC011, NRG-CC013, NRG-CC014, NRG-CC015, NRG-GU015, and NRG-HN014. Space is limited so register now and reserve your seat. The next webinar training is scheduled for October 8, 2025.

Safety updates and Investigator Brochure (*IB) updates have been issued for the following studies:

*The current version of the Investigator Brochure Documents for Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI)-sponsored trials are available for access via the Cancer Therapy Evaluation Program (CTEP) Agent Inventory Management System (AURORA) application. Log-in using your Identity and Access Management (IAM) or ID.me credentials and provide the requested information to access the document.

Every site principal investigator is responsible for reviewing this document. The Investigator Brochure is for use by the site principal investigator and any study personnel under his/her supervision who need to know the contents for the conduct of a clinical trial, including Institutional Review Board(s) or Independent Ethics Committee(s).

1. NRG-BR009/OFSET Study Webinars

The BR009 Protocol Leadership is planning webinars for the NRG-BR009 trial on September 30, October 6, 7, and 9. There will be an overview of the protocol and frequently asked questions will be discussed. There will also be time for questions and answers. These webinars are intended for BR009 research staff at the sites, for sites that currently have NRG-BR009 open, as well as those interested in opening BR009 at their site in the future. To register to attend one of the sessions please click here. If you have questions about the webinars, please contact the Clinical Coordinating Department at ccdPGH@NRGOncology.org

2. NRG-CC008 Webinar

The study chairs and team will be hosting a webinar on Friday, October 3, 2025, 12:00 – 1:00 PM ET, to discuss baseline PRO completion, subject retention/long-term follow-up, address protocol amendment questions and STIC lesions. We’d also like to hear from participating sites about their experiences with this trial. Please register in advance for this meeting here. After registering, you will receive a confirmation email containing information about joining the meeting.

11. NRG Member Information Form

We are excited to introduce the NRG Member Information Data Collection Initiative that will allow us to create a comprehensive member database, enabling us to better understand and serve our members. Your information will be kept secure and confidential, ensuring that your privacy is always protected. All members are encouraged to complete the form or indicate that they wish to opt out of this data collection initiative. 

Scan the QR code below or click this link to access the form. 

Questions? Read more here

REMINDER: Any manuscript or abstract resulting from research conducted under the auspices of our NCI grant awards must be processed through the NRG Publications Office before being submitted to the journal or association.

Please reach out to NRG-Publications@NRGOncology.org as a first step to ensure all requirements are met.

Please note the following upcoming meetings and abstract submission deadlines

UPCOMING MEETINGS

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; Oct 22-26, 2025; Boston, MA

AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; Sep 18-21, 2025; Baltimore, MD

American Society for Radiation Oncology (ASTRO); Sep 28-Oct 1, 2025; San Francisco, CA

European Society for Medical Oncology (ESMO); Oct 17-21, 2025; Berlin, Germany

International Society for Quality-of-Life Research (ISOQOL); Oct 22-25, 2025; Milwaukee, WI

PA Breast Cancer Coalition (PBCC); Oct 15, 2025; Harrisburg, PA

Radiological Society of North America (RSNA); Nov 30-Dec 4, 2025; Chicago, IL

Society for Neuro-Oncology (SNO); Nov 19-23, 2025; Honolulu, HI

Society for Immunotherapy of Cancer (SITC); Nov 5-9, 2025; National Harbor, MD

UPCOMING ABSTRACT SUBMISSION DEADLINES

American Association for Cancer Research (AACR); Apr 17-22, 2026; San Diego, CA; Due to publications committee Nov 4, 2025; Submission deadline Nov 18, 2025; LBA and Clinical Trials Jan 6, 2026

American Society of Clinical Oncology (ASCO); May 29-Jun 2, 2026; Chicago, IL; Due to publications committee Jan 13, 2026; Submission deadline Jan 27, 2026, 11:59 pm ET; LBA Mar 9, 2026, 12:00 pm ET (placeholder required)

American Society of Clinical Oncology (ASCO) GI; Jan 8-10, 2026; San Francisco, CA; Due to publications committee Oct 7, 2025; Submission deadline Oct 21, 2025, 11:59 pm ET LBA Oct 9, 2025, 12:00 pm ET (placeholder required)

American Society of Clinical Oncology (ASCO) GU; Feb 26-28, 2026; San Francisco, CA; LBA Nov 20, 2025, 12:00 pm ET (placeholder required)

American Society of Colon and Rectal Surgeons (ASCRS); May 9-12, 2026; Tampa, FL; Due to publications committee Sep 30, 2025; Submission deadline Oct 14, 2025, 11:59 pm ET; LBA and Clinical Trials Jan 28, 2026

European Society of Gynaecological Oncology (ESGO); Feb 26-Mar 1, 2026; Copenhagen, Denmark; Due to publications committee Oct 17, 2025; Submission deadline Oct 31, 2025, 23:59 CET; LBA Jan 15, 2026

European Society for Radiotherapy and Oncology (ESTRO); May 15-19, 2026; Stockholm, Sweden; Due to publications committee Oct 29, 2025; Submission deadline Nov 12, 2025; LBA Apr 8, 2026

International Gynecologic Cancer Society (IGCS); Nov 5-7, 2025; Cape Town, South Africa; LBA Sep 29, 2025 (placeholder required)

San Antonio Breast Cancer Symposium (SABCS); Dec 9-12, 2025; San Antonio, TX; LBA Sep 30, 2025, 11:59 pm CT

SSO - Advanced Cancer Therapies; Feb 14-16, 2026; Fort Lauderdale, FL; Due to publications committee Oct 6, 2025; Submission deadline Oct 20, 2025, 11:59 pm CT

Society of Urologic Oncology (SUO); Dec 2-5, 2025; Dallas, TX; LBA Oct 1, 2025